Peel Hunt reiterated their buy rating on shares of PureTech Health (LON:PRTC) in a research note released on Thursday, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts have also commented on PRTC. Jefferies Financial Group increased their price target on PureTech Health from GBX 280 ($3.66) to GBX 340 ($4.44) and gave the company a buy rating in a research report on Friday, July 5th. Liberum Capital increased their price target on Moneysupermarket.Com Group from GBX 520 ($6.79) and gave the company a buy rating in a research report on Thursday.
LON PRTC opened at GBX 240 ($3.14) on Thursday. The stock has a market cap of $677.99 million and a price-to-earnings ratio of -15.00. The company has a fifty day moving average of GBX 223.52. PureTech Health has a 12 month low of GBX 135 ($1.76) and a 12 month high of GBX 239 ($3.12). The company has a debt-to-equity ratio of 7.19, a current ratio of 0.98 and a quick ratio of 0.95.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.